PR Newswire Clinical TrialsOriginal article
Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026
ConferenceCadonilimabNeutral
AI Analysis
Summary
Akeso presented updated clinical data on cadonilimab combination therapy for advanced NSCLC resistant to PD-(L)1 inhibitors at the 2026 European Lung Cancer Congress, with a median follow-up of 21.45 months in a prospective, open-label, single-arm multicenter trial.
Clinical Trial Data
Outcome Details
Updated data presented at ELCC 2026 with median follow-up of 21.45 months
Importance:5/10
Sentiment:
0.00
NSCLCcombination therapyPD-(L)1 resistantconference presentationoncology
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on April 7, 2026 3:28 AM